Jefferies Assumes Vanda Pharmaceuticals (VNDA) at Buy

October 6, 2016 6:49 AM EDT
Get Alerts VNDA Hot Sheet
Price: $15.25 +0.66%

Rating Summary:
    7 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 23 | Down: 24 | New: 8
Trade VNDA Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies assumes coverage on Vanda Pharmaceuticals (NASDAQ: VNDA) with a Buy rating and a price target of $23.00 (from $15.00).

Analyst Matthew Andrew commented, "Assuming coverage with a Buy Rating and $23 price target. While VNDA shares are +38% since the positive 8/25/16 Fanapt IP ruling, we see further LT upside to shares from 1) continuing improvement in U.S. Fanapt sales/scrips, 2) steady growth of Hetlioz in the U.S./EU-5, and 3) pipeline contributions from Hetlioz in Jet Lag Disorder (JLD) and tradipitant in gastroparesis starting in 2019/2021. 2017 is a key year for the pipeline with four Ph. II/III readouts."

For an analyst ratings summary and ratings history on Vanda Pharmaceuticals click here. For more ratings news on Vanda Pharmaceuticals click here.

Shares of Vanda Pharmaceuticals closed at $16.25 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Hot New Coverage, New Coverage

Related Entities

Jefferies & Co

Add Your Comment